Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Longitudinal analysis of melanoma-specific T-cell immunity during treatment of advanced melanoma
NL-OMON36481Active, not recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Apr 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of ipilimumab and GC101 TIL + pembrolizumab in melanoma and cutaneous malignancy, sponsored by Leiden University Medical Center. Primary endpoint: Immunologic monitoring. Started Apr 2011; status: active, not recruiting.
02
Drugs
ipilimumabGC101 TIL + pembrolizumab
03
Conditions
melanomacutaneous malignancy
Beyond the preview
Go deeper on NL-OMON36481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36481.